Financial Data and Key Metrics Changes - The company raised and deployed over $1.4 billion in gross new fee-paying AUM, marking a record fundraising quarter [5] - Revenue for the first quarter was $67.7 million, a 2% increase year-over-year [18] - Fee-paying assets under management increased by 10% year-over-year to $26.3 billion [18] - GAAP net income decreased to $4.7 million from $5.2 million year-over-year [21] - Adjusted net income (ANI) was $23.5 million, representing an 8% decrease from the previous year [21] - The FRE margin was 45% in the first quarter [22] Business Line Data and Key Metrics Changes - Private equity strategies raised and deployed $1.2 billion, while venture capital solutions raised $82 million and private credit strategies added $162 million to fee-paying AUM [19] - The average fee rate in the first quarter was 102 basis points, with expectations to average 103 basis points for the year [19] Market Data and Key Metrics Changes - The company closed the acquisition of Qualitas Funds, adding $1 billion to fee-paying AUM and expanding its global LP base [7][12] - The company expects to have more than 15 funds in the market throughout the year, indicating strong demand for its investment strategies [6] Company Strategy and Development Direction - The strategic plan focuses on optimizing organizational structure, driving organic growth, and enhancing transparency [8] - The company aims to deepen its engagement with larger institutional investors, such as insurance companies and pension funds [11] - The acquisition of Qualitas Funds is seen as a strategic fit to expand geographic footprint and asset class exposure [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating potential market volatility due to a robust strategic roadmap [9] - The company anticipates at least $4 billion in organic gross fundraising for 2025 and double-digit revenue growth [7] - Management highlighted the resilience of the middle and lower middle market, which is less affected by public market fluctuations [14] Other Important Information - The company announced a 7% increase in its quarterly dividend to $3.75 per share [22] - The cash tax rate for 2025 is expected to be in the low single digits, benefiting from tax assets [26] Q&A Session Summary Question: Clarification on catch-up fees related to RCP Direct fund - Management clarified that the April 10 date was the announcement date, not the close date [30] Question: Insights on cross-marketing with 5,000 LPs - Management discussed efforts to optimize data and capitalize on synergies with the Qualitas Funds team [34] Question: Guidance on step downs and expirations - Management confirmed that guidance on step downs and expirations remains unchanged [38] Question: Impact of Qualitas on tax and M&A - Management noted that the acquisition structure will not change tax amortization and highlighted a robust M&A market [44][45] Question: Sentiment from endowments and foundations - Management reported little to no impact from recent volatility on their LP base and sees opportunities for liquidity solutions [56] Question: Fund contributions to the $4 billion target - Management expressed excitement about various funds, particularly in NAV lending and secondaries, contributing to the fundraising target [58]

Group 1 - TruBridge reported quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share, but showing an increase from $0.19 per share a year ago, resulting in an earnings surprise of -2.70% [1] - The company posted revenues of $87.21 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.51%, and compared to year-ago revenues of $83.25 million [2] - TruBridge has topped consensus revenue estimates four times over the last four quarters, indicating a consistent performance in revenue generation [2] Group 2 - The stock has increased approximately 29.1% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.28 on revenues of $87.33 million, and for the current fiscal year, it is $1.79 on revenues of $349.64 million [7] Group 3 - The Medical Info Systems industry, to which TruBridge belongs, is currently in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The Zacks Rank for TruBridge is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]

Financial Data and Key Metrics Changes - Adjusted EBITDA nearly doubled to $18,200,000 from $10,000,000 year-over-year, with cash flow from operations increasing over $7,000,000, and net leverage ratio improved to 2.4 times from 4.4 times [4][5][20] - Revenue for the quarter was $87,200,000, reflecting a year-over-year increase of 3.7%, with adjusted EBITDA margin at 20.9%, up 860 basis points from the prior year [24][27] Business Line Data and Key Metrics Changes - Bookings totaled $22,000,000, down from $24,000,000 year-over-year, but up from $14,000,000 in Q4 2024, with financial health bookings at $13,000,000, a 50% sequential increase [6][8] - Patient care bookings were $9,000,000, a 60% sequential increase, with customer retention at 98% excluding Sentric [8][15] Market Data and Key Metrics Changes - Financial health represented 64% of total revenue at $56,100,000, a 5% increase year-over-year, while patient care revenue was $31,100,000, up 1.3% year-over-year [25][26] - Gross margins improved to 54.7%, with financial health gross margins at 51.6%, up 700 basis points, while patient care gross margins remained flat at 60.4% [26][27] Company Strategy and Development Direction - The company is focusing on enhancing customer service and operational efficiency, with plans to standardize global hiring processes and increase offshore support to 60% by the end of 2025 [12][14] - There is a clear demand for automation in revenue cycle management, with plans to leverage AI to drive improvements [13][14] Management's Comments on Operating Environment and Future Outlook - Management noted a cautious sentiment among customers due to policy uncertainties and potential changes in Medicare expansion and reimbursement [36][38] - The company remains committed to improving profitability and cash flow management, with expectations for continued revenue growth despite external challenges [19][29] Other Important Information - The company will transition to reporting bookings solely on an annual contract value (ACV) basis by 2026, which is expected to clarify revenue potential [9][24] - Cash from operations was $5,400,000, with accounts receivable down 12% and days sales outstanding (DSO) improving by twelve days year-over-year [20][28] Q&A Session Summary Question: How are policy changes affecting customer purchasing decisions? - Management indicated that while there is caution among customers due to policy uncertainties, they have not seen immediate impacts on sales cycles [34][36] Question: What are the expected net savings from reducing staffing duplicity? - Expected savings from offshore staffing are projected in the mid-single-digit millions for the full year, with ongoing evaluations of staffing efficiency [40][42] Question: Can you elaborate on Meredith's plan for client retention? - The focus is on enhancing client satisfaction and retention through improved operational efficiency and quality output from the offshore team [47][49] Question: What is the strategy regarding automation and offshore labor? - The company aims for a 60% offshore staffing mix while continuing to invest in automation to improve efficiency and standardization of processes [51][53] Question: How should we view the decline in non-subscription patient care bookings? - The shift to a SaaS model has affected the revenue structure, with a focus on recurring revenue rather than one-time fees [68][70] Question: Were the recent financial health deals concentrated in the lower or upper end of the 100-400 bed range? - One deal was just over 100 beds, while the other was closer to the upper end, indicating a balanced approach in targeting this market segment [73][75]

Financial Data and Key Metrics Changes - Adjusted EBITDA for Q1 2025 nearly doubled to $18,200,000 compared to $10,000,000 in Q1 2024, with cash flow from operations increasing over $7,000,000 [5][20] - Revenue for Q1 2025 was $87,200,000, reflecting a year-over-year increase of 3.7%, and adjusted EBITDA margin improved to 20.9%, up 860 basis points from the prior year [24][28] - Net leverage ratio improved to 2.4 times in Q1 2025, down from 4.4 times a year ago [5][20] Business Line Data and Key Metrics Changes - Bookings for Q1 2025 totaled $22,000,000, down from $24,000,000 year-over-year, with financial health bookings at $13,000,000, a 50% sequential increase [6][7] - Patient care bookings were $9,000,000, a 60% sequential increase, with customer retention at 98% excluding Sentric [7][15] - Financial health represented 64% of total revenue at $56,100,000, a 5% increase year-over-year, while patient care revenue was $31,100,000, up 1.3% [26][27] Market Data and Key Metrics Changes - The company noted ongoing uncertainty related to future healthcare funding and potential impacts of tariffs on customer decision-making [10] - The shift to a SaaS model has affected the revenue mix, with a focus on recurring revenue rather than one-time fees [70] Company Strategy and Development Direction - The company is increasing investments in operational initiatives, including standardizing the global hiring process and enhancing customer service [12][14] - There is a focus on automation and leveraging AI to improve revenue cycle management [13][55] - The company aims to transition all bookings to an annual contract value (ACV) basis by 2026 for clearer revenue recognition [9][24] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding customer sentiment amid policy changes and potential impacts on hospital budgets [40] - The company is committed to improving forecasting processes and maintaining revenue expectations while increasing adjusted EBITDA guidance for the full year [30][31] Other Important Information - The company ended Q1 2025 with $10,100,000 in cash, compared to $4,100,000 a year ago, and net debt of $158,000,000 [29] - Operating expenses decreased to 45.3% of total revenue, down from 51.1% a year ago, due to cost optimization actions [28] Q&A Session Summary Question: Impact of policy changes on sales cycle - Management noted that while there is cautious sentiment regarding policy changes, they have not seen immediate impacts on sales conversations [39] Question: Potential net savings from staffing changes - Management expects mid-single-digit million savings from reducing duplicity in offshore and onshore staffing [43] Question: Meredith's plan of action and client retention - Focus is on improving client delight and retention through better training and infrastructure as the offshore operations scale up [50] Question: Non-subscription component of patient care bookings - Management acknowledged a shift to recurring revenue models and noted that new offerings are primarily based on the SaaS model [70] Question: Financial health client wins in the hospital market - Management confirmed that recent wins were in both the lower and upper ends of the 100 to 400 bed range, emphasizing the need for RCM services in this segment [74]

Revenue Performance - TruBridge reported total revenues of $87.2 million for Q1 2025, an increase of 3.1% compared to $84.1 million in Q1 2024[5] - Financial Health revenue was $56.1 million, representing 64% of total revenue, up from $53.4 million in the previous year[5] - TruBridge's recurring revenue accounted for 94% of total revenue in Q1 2025[5] - Total revenues for the three months ended March 31, 2025, were $87,208,000, compared to $84,117,000 in 2024, reflecting a year-over-year growth of 3%[34] - Recurring revenues for the three months ended March 31, 2025, increased to $81,970,000 from $80,660,000 in 2024, indicating a stable revenue stream[34] Profitability - The company achieved a GAAP net income of $0.5 million, compared to a net loss of $1.9 million in Q1 2024[5] - Non-GAAP net income increased to $5.2 million, up from $3.4 million year-over-year[5] - Net income for the three months ended March 31, 2025, was $459,000, a significant improvement from a net loss of $1,854,000 in the same period of 2024[17] - The company reported a Non-GAAP net income of $5,192,000 for the three months ended March 31, 2025, compared to $3,369,000 in 2024, marking a 54% increase[32] Adjusted EBITDA - Adjusted EBITDA for Q1 2025 was $18.2 million, significantly higher than $10.3 million in Q1 2024[5] - Adjusted EBITDA for the three months ended March 31, 2025, was $18,231,000, representing a 76% increase from $10,324,000 in 2024[27] - The company’s Adjusted EBITDA margin improved to 20.9% in 2025 from 12.3% in 2024, reflecting enhanced operational efficiency[29] Future Guidance - TruBridge expects total bookings of $22.0 million for Q2 2025, down from $23.6 million in Q2 2024[5] - The company anticipates total revenue for the full year 2025 to be between $345 million and $360 million, unchanged from previous guidance[6] - The company plans to transition to reporting bookings on an Annual Contract Value (ACV) basis starting January 2025, enhancing revenue recognition clarity[24] Cash Flow and Financial Health - Cash and cash equivalents at the end of the period were $10,124,000, down from $12,324,000 at the beginning of the period[17] - The company experienced a net cash provided by operating activities of $5,760,000 for the three months ended March 31, 2025, a turnaround from a cash used of $2,034,000 in 2024[17] - The leverage ratio improved to 2.4x following additional debt repayment[3] Non-GAAP Financial Measures - Non-GAAP net income is derived from GAAP net income with adjustments for amortization, stock-based compensation, and nonrecurring charges, reflecting core profitability[39] - Non-GAAP EPS is calculated from Non-GAAP net income divided by diluted weighted average shares outstanding, offering a clearer view of earnings per share[39] - Stock-based compensation is excluded from non-GAAP measures as it may not correlate directly with business performance and varies significantly over periods[40] - Severance and other nonrecurring charges are excluded from non-GAAP measures due to their nonrecurring nature, which may not reflect ongoing operational performance[40] - Non-cash interest expense is excluded from non-GAAP measures as it relates to specific transactions and may not reflect underlying business performance[40] - The gain on the sale of AHT is excluded from non-GAAP measures as it pertains to a specific transaction and does not correlate with ongoing operations[40] - The company emphasizes that non-GAAP financial measures are not alternatives to GAAP measures and have limitations in reflecting overall financial performance[39] - Investors are encouraged to review the "Unaudited Reconciliation of Non-GAAP Financial Measures" for a comprehensive understanding of financial performance[39]

Financial Data and Key Metrics Changes - In Q4 2024, the company reported revenue of $87.4 million, an increase of 2% year-over-year, and adjusted EBITDA of $17.2 million, which was a 44% increase compared to the previous year [8][10]. - The full year revenue for 2024 was $339 million, with adjusted EBITDA of $53 million, exceeding the high end of guidance ranges [10][56]. - Cash flow from operations improved to $10.3 million in Q4, a $23 million increase compared to the previous year, and full year cash flow from operations reached $32 million, up from just over $1 million in 2023 [9][38]. Business Line Data and Key Metrics Changes - Financial Health revenue for Q4 was $54.7 million, up 7.3% year-over-year, representing approximately 63% of total revenue, driven by core CBO offerings and Viewgol [49]. - Patient Care revenue decreased by 6.3% year-over-year to $32.7 million, impacted by the divestiture of AHT and the sunsetting of Centriq, although excluding these, revenue was higher year-over-year [50]. - Total bookings for the year were $82 million, with Financial Health bookings flat year-over-year at $49 million and Patient Care bookings up 6% to $33 million [54][56]. Market Data and Key Metrics Changes - The company noted that 75% of the time, no decision remains the reason for not closing a deal, rather than losing to a competitor, indicating a potential market opportunity [17]. - The market for hospitals with 100 to 400 beds grew from 5% to over 20% of financial health opportunities in the pipeline from 2023 to 2024 [16]. Company Strategy and Development Direction - The company plans to continue focusing on improving customer satisfaction, retention, and profitability while expanding its presence in the 100 to 400 bed hospital market [18][34]. - A new leadership was brought in for the financial health business unit to enhance customer satisfaction and pipeline expansion [19][20]. - The company aims to double the percentage of CBO clients supported by the global workforce from 30% to 60% by the end of 2025 [24]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, despite some uncertainty regarding healthcare funding changes from the government, which could impact deal timing [13][106]. - The company expects to achieve mid-single digit revenue growth and EBITDA margins in the mid-20s over the next few years [32][60]. - Management highlighted the importance of improving forecasting and accounting processes to enhance predictability and control [46][47]. Other Important Information - The company reduced its leverage ratio from over 4 times to 3 times and plans to continue de-levering [11][40]. - Total gross margins improved to 53% in Q4, up 390 basis points year-over-year, with Financial Health gross margins at 49.1% and Patient Care gross margins at 59.6% [51][52]. Q&A Session Summary Question: Can you speak to the visibility on closing remaining deals expected to close in Q4? - Management indicated that some deals were delayed due to uncontrollable factors but remain optimistic about closing them in the first half of 2025 [64][66]. Question: What are the expectations for sales and marketing initiatives in 2025? - The company plans to increase investments in marketing to enhance brand exposure and drive cross-sell opportunities, particularly targeting hospitals that do not currently use their EHR [68][70]. Question: How does the company view the growth among its two segments for 2025? - Financial Health is expected to be the primary growth driver, while Patient Care is anticipated to see low single-digit growth [85][87]. Question: Can you provide insights on the demand environment and metrics like pipeline and win rate? - The company noted that about 40% of bookings come from opportunities opened and closed within the same quarter, and the win rate is above 50% when excluding no-decision outcomes [89][95]. Question: How does the company plan to handle the 60 renewals in 2025? - The renewals are spread throughout the year, and the company is focused on ensuring customer satisfaction to retain these clients [99][103].

Company Performance - Senseonics Holdings reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, and an improvement from a loss of $0.03 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $8.3 million for the quarter ended December 2024, in line with the Zacks Consensus Estimate, and an increase from $8 million in the same quarter last year [2] - Over the last four quarters, Senseonics has surpassed consensus revenue estimates three times [2] Stock Performance - Senseonics shares have increased approximately 62.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $8.36 million, and for the current fiscal year, it is -$0.12 on revenues of $35.86 million [7] Industry Outlook - The Medical Info Systems industry, to which Senseonics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Senseonics' stock performance [5][6]